TY - JOUR
T1 - Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries
AU - Kurbatova, Ekaterina V.
AU - Dalton, Tracy
AU - Ershova, Julia
AU - Tupasi, Thelma
AU - Caoili, Janice Campos
AU - Walt, Martie Van Der
AU - Kvasnovsky, Charlotte
AU - Yagui, Martin
AU - Bayona, Jaime
AU - Contreras, Carmen
AU - Leimane, Vaira
AU - Via, Laura E.
AU - Kim, Heejin
AU - Akksilp, Somsak
AU - Kazennyy, Boris Y.
AU - Volchenkov, Grigory V.
AU - Jou, Ruwen
AU - Kliiman, Kai
AU - Demikhova, Olga V.
AU - Peter Cegielski, J.
N1 - Publisher Copyright:
© 2015 Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2015
Y1 - 2015
N2 - Data from a large multicenter observational study of patients with multidrug-resistant tuberculosis (MDR TB) were analyzed to simulate the possible use of 2 new approaches to treatment of MDR TB: a short (9-month) regimen and a bedaquiline-containing regimen. Of 1,254 patients, 952 (75.9%) had no resistance to fluoroquinolones and second-line injectable drugs and thus would qualify as candidates for the 9-month regimen; 302 (24.1%) patients with resistance to a fluoroquinolone or second-line injectable drug would qualify as candidates for a bedaquiline-containing regimen in accordance with published guidelines. Among candidates for the 9-month regimen, standardized drug-susceptibility tests demonstrated susceptibility to a median of 5 (interquartile range 5–6) drugs. Among candidates for bedaquiline, drug-susceptibility tests demonstrated susceptibility to a median of 3 (interquartile range 2–4) drugs; 26% retained susceptibility to <2 drugs. These data may assist national TB programs in planning to implement new drugs and drug regimens.
AB - Data from a large multicenter observational study of patients with multidrug-resistant tuberculosis (MDR TB) were analyzed to simulate the possible use of 2 new approaches to treatment of MDR TB: a short (9-month) regimen and a bedaquiline-containing regimen. Of 1,254 patients, 952 (75.9%) had no resistance to fluoroquinolones and second-line injectable drugs and thus would qualify as candidates for the 9-month regimen; 302 (24.1%) patients with resistance to a fluoroquinolone or second-line injectable drug would qualify as candidates for a bedaquiline-containing regimen in accordance with published guidelines. Among candidates for the 9-month regimen, standardized drug-susceptibility tests demonstrated susceptibility to a median of 5 (interquartile range 5–6) drugs. Among candidates for bedaquiline, drug-susceptibility tests demonstrated susceptibility to a median of 3 (interquartile range 2–4) drugs; 26% retained susceptibility to <2 drugs. These data may assist national TB programs in planning to implement new drugs and drug regimens.
UR - http://www.scopus.com/inward/record.url?scp=84929395533&partnerID=8YFLogxK
U2 - 10.3201/eid2106.141329
DO - 10.3201/eid2106.141329
M3 - Artículo
C2 - 25988299
AN - SCOPUS:84929395533
SN - 1080-6040
VL - 21
SP - 977
EP - 983
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 6
ER -